التفاصيل البيبلوغرافية
| العنوان: |
Health-related quality of life as an endpoint in oncology phase I trials: a systematic review |
| المؤلفون: |
Frédéric Fiteni, Isabelle Le Ray, Ahmad Ousmen, Nicolas Isambert, Amélie Anota, Franck Bonnetain |
| المصدر: |
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019) |
| بيانات النشر: |
BMC, 2019. |
| سنة النشر: |
2019 |
| المجموعة: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: |
Health-related quality of life, Phase I trial, Endpoint, Recommended phase II dose, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: |
Abstract Background Phase I trials aim to identify the recommended dose for further development. Health-related quality of life (HRQoL) could be a complement to the usual National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale to detect adverse events and define the doses. The objective of this study is to review the phase I in oncology which used HRQoL as endpoint. Methods A search in PubMed database identified phase I trials in oncology with HRQoL as endpoint, published between January 2012 to May 2016. Hematological and pediatric phase I were excluded. Results A total of 1333 phase I were identified and 15 trials were identified with HRQoL as endpoint (1.1%). The European Organisation for Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was the most frequently used instrument: 5 studies (33.3%). The targeted dimensions of HRQoL and the minimal clinically important difference were prespecified in 1 study (6.7%) and 2 studies (13.3%), respectively. Twelve studies (80%) described the statistical approach to analyze HRQoL data. Eight studies used the mean change from baseline (60%) to analyse longitudinal HRQoL data, two the mean score at certain times (13.3%), one the linear mixed model for repeated measures (6.7%), one the time to HRQoL score deterioration (6.7%), one percentage of patient-reported symptoms (6.7%). None of the studies used HRQoL to determine the recommended doses. Conclusion Few phase I studies used HRQoL as endpoint and among studies with HRQoL as endpoint, the methodology of HRQoL measurement and statistical analysis was heterogeneous. HRQoL. endpoint not used for assessing the recommended phase II doses. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1471-2407 |
| Relation: |
http://link.springer.com/article/10.1186/s12885-019-5579-3; https://doaj.org/toc/1471-2407 |
| DOI: |
10.1186/s12885-019-5579-3 |
| URL الوصول: |
https://doaj.org/article/efd2520838614df78ffdffdb1de2b903 |
| رقم الانضمام: |
edsdoj.fd2520838614df78ffdffdb1de2b903 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder